EMA Authorised: Onglyza (saxagliptin) — AstraZeneca AB

View source ↗

Summary

Onglyza (saxagliptin) has been authorised in the European Union for the treatment of type 2 diabetes mellitus, by AstraZeneca AB.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: AstraZeneca AB. Decision date: 19/04/2023